liposomal irinotecan + fruquintinib + sintilimab

This combination therapy consists of **liposomal irinotecan**, **fruquintinib**, and **sintilimab**. Liposomal irinotecan is a nanoparticle formulation of a topoisomerase I inhibitor designed to improve the pharmacokinetic profile and intratumoral concentration of the active metabolite SN-38. Fruquintinib is a highly selective and potent small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, thereby inhibiting tumor angiogenesis. Sintilimab is a recombinant humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody that restores T-cell mediated anti-tumor immune responses. The regimen is currently being evaluated as a second-line or later treatment for patients with advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, aiming to provide synergistic anti-tumor activity through combined cytotoxicity, anti-angiogenesis, and immune checkpoint inhibition.

Brand names

ElunateTyvyt

Other names

liposomal irinotecan + fuquitinib + sindilizumabirinotecan liposome + fruquintinib + sintilimab